Advancing Therapeutic Development for Pulmonary Morbidities Associated with Preterm Birth

Area of Science:

• Neonatology
• Pulmonology
• Clinical Trials

Background:

• Chronic pulmonary and respiratory conditions in preterm infants are not well understood, hindering effective treatment development.
• Current clinical endpoints for preterm neonates lack validation and fail to adequately predict long-term health outcomes.
• Developing new therapies is challenged by the incomplete characterization of disease endotypes and outcome measures.

Purpose of the Study:

• To propose a research agenda for advancing the development of clinical trial endpoints for preterm infants with chronic respiratory conditions.
• To identify key steps for creating validated, clinically meaningful endpoints that reflect meaningful health outcomes.
• To emphasize the need for multi-stakeholder collaboration in therapeutic development for this population.

Main Methods:

• Convening a 2018 expert workshop to gather input on endpoint development.
• Reviewing existing endpoints for preterm neonates and their limitations.
• Discussing strategies for characterizing disease endotypes and optimizing endpoint selection.
• Highlighting the importance of data standardization and novel clinical trial designs.

Main Results:

• A proposed research agenda focusing on endpoint and treatment development for chronic respiratory conditions in preterm birth survivors.
• Identification of critical areas for improvement, including endpoint validation and disease endotype characterization.
• Emphasis on the necessity of linking short- and long-term endpoints to meaningful health outcomes.

Conclusions:

• Further evaluation of existing endpoints and improved characterization of disease endotypes are crucial.
• Optimized short- and long-term endpoints linked to meaningful health outcomes are needed.
• Multi-stakeholder collaboration and standardized data collection are vital for advancing therapeutic development.